Delivery Order HHSF223201310033I-HHSF22301003T
Award Date
9/20/17
Potential Completion Date
9/29/22
Potential Value
$1.8M
Federal Agency
Food and Drug Administration
Ultimate Awardee
Lovelace Biomedical Research Institute
PSC Category
R499 - Support- Professional: Other
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm-fixed-price delivery order under the "In Vivo Toxicology of Tobacco 2015-2020" indefinite-delivery, indefinite-quantity (IDIQ) contract, awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization. The contract is for studying the effects of menthol on the pharmacokinetics of nicotine and tobacco-specific nitrosamines, with a ceiling value of $1,640,749.00 and...
This is a $1,251,731.00 firm fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The contract, which has no set-aside designation, is part of Task Order 2 under a larger contract vehicle and is focused on examining the influence of synthetic cooling agents on cigarette sensory and subjective effects, as well as use behavior. Lovelace Biomedical Research...
This is a firm fixed-price delivery order awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The $3,872,713 task order, which is not set aside, is for a study to evaluate whether reductions in biomarkers of exposure, biomarkers of potential harm, and other health risk markers are proportional to reductions in cigarette smoking when switching to electronic nicotine delivery systems. Lovelace...
This firm fixed-price delivery order was awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $2,472,244.00 contract is for the evaluation of e-cigarette aerosol in in vivo nonclinical models and was issued under the In Vivo Toxicology of Tobacco 2015-2020 indefinite delivery, indefinite quantity (IDIQ) contract. Lovelace Biomedical Research Institute has...
This federal contract award, valued at $1,403,705.20, was issued by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The contract is a delivery order issued under the Tobacco Products Pharmacology Study master indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. The contract does not have a set-aside designation. LBERI, a non-profit contract research organization,...
This is a firm fixed-price delivery order issued by the Department of Health and Human Services Food and Drug Administration under the In Vivo Toxicology of Tobacco 2015-2020 indefinite delivery/indefinite quantity (IDIQ) contract. The $1,408,956.00 task order was awarded to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization, to perform detection and characterization of DNA adducts generated by tobacco flavorants in aerosol...
This is a delivery order contract awarded by the Department of Health and Human Services Food and Drug Administration to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a non-profit organization, for a project titled "CYTOTOXICITY OF COMMON SOLVENTS USED IN LIQUID NICOTINE FORMULATIONS". The contract has a potential value of $1,149,919.00 and a completion date of April 15, 2021. This delivery order is part of a larger indefinite delivery/indefinite quantity...
This is a delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a non-profit research organization, to develop a standard guideline protocol for rodent tobacco smoke inhalation studies. The contract has a ceiling value of $1,373,599.00 and is a firm fixed-price task order issued under the "In Vivo Toxicology of Tobacco 2015-2020" indefinite-delivery, indefinite-quantity (IDIQ) contract. The...
This is a $897,471 firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), doing business as Inhalation Toxicology Research Institute. The contract is part of a larger In Vivo Toxicology of Tobacco 2015-2020 indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. LBERI, a non-profit contract research organization, will provide preclinical research services to support the...
This firm-fixed-price delivery order was issued under the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) "In Vivo Toxicology of Tobacco 2015-2020" indefinite-delivery, indefinite-quantity (IDIQ) contract. The $1,412,105.00 contract was awarded to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), doing business as Inhalation Toxicology Research Institute, a non-profit contract research organization. The contract is for the...